Craig B. Reynolds Sells 2,053 Shares of Masimo Co. (NASDAQ:MASI) Stock

Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares of the company’s stock, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Masimo Price Performance

Masimo stock opened at $168.21 on Friday. The company has a market capitalization of $9.07 billion, a price-to-earnings ratio of 116.01 and a beta of 1.03. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The stock’s 50 day moving average is $174.84 and its 200-day moving average is $157.36.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Equities research analysts expect that Masimo Co. will post 4.1 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp purchased a new stake in shares of Masimo during the fourth quarter worth $27,000. UMB Bank n.a. grew its stake in shares of Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 123 shares during the last quarter. Trust Co. of Vermont purchased a new stake in shares of Masimo during the fourth quarter worth about $33,000. Blue Trust Inc. boosted its holdings in shares of Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 64 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MASI has been the subject of a number of recent analyst reports. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Wells Fargo & Company raised their price target on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Piper Sandler increased their price objective on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, Raymond James raised their target price on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.